Unlocking a New Paradigm in Cancer Therapeutics
We are a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Using our proprietary Spyglass platform, we identify targets essential for ecDNA functionality, then design and develop small molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets and prevent cancer cells from using ecDNA to grow, adapt, and become resistant to existing therapies.
Minimum 15 minutes delayed. Source:
